Antifungal drugs for invasive Candida infections (ICI) in neonates: future perspectives

Abstract

Fungal infections may complicate the neonatal clinical course, and the spectrum of therapies for their treatment in the perinatal period is limited. Polyenes, Azoles and Echinocandins represent the three classes of antifungal drugs commonly used in the neonatal period. The present review provides an overview about the most recent therapeutic strategies for the treatment of fungal infections in neonates.

Keywords:neonate, fungal infection, sepsis, lock therapy, polyenes, azoles, echinocandins, candidemia

Bersani I., Piersigilli F., Goffredo B.M., Santisi A., Cairoli S., Ronchetti M.P., Auriti C. Antifungal drugs for invasive Candida infections (ICI) in neonates: future perspectives. Front Pediatr. 7: 375. DOI: 10.3389/fped.2019.00375

Литература/References

1. Cotter G., Kavanagh K. Adherence mechanisms of Candida albicans. Br J Biomed. Sci. 2000; 57: 241-9.

2. Hube B., Naglik J. Extracellular hydrolases. In: Calderone R., ed. Candida and Candidiasis. Washington DC: ASM Press; 2002: 107 p.

3. Arsenault A.B., Bliss J.M. Neonatal candidiasis: new insights into an old problem at a unique host-pathogen interface. Curr Fungal Infect Rep. 2015; 9: 246-52. DOI: 10.1007/s12281-015-0238-x

4. Benjamin D.K. Jr., Stoll B.J., Fanaroff A.A., McDonald S.A., Oh Higgins W., et al. National institute of child health and human development neonatal research network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006; 117: 84-92. DOI: 10.1542/peds.2004-2292

5. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehren-kranz R.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002; 110: 285-91. DOI: 10.1542/peds.110.2.285

6. Friedman S., Richardson S.E., Jacobs S.E., O’Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J. 2000; 19: 499-504. DOI: 10.1097/00006454-200006000-00002

7. Saiman L., Ludington E., Pfaller M., Rangel-Frausto S., Wiblin R.T., Dawson .J, et al. Risk factors for candidemia in neonatal intensive care unit patients. The national epidemiology of mycosis survey study group. Pediatr Infect Dis J. 2000; 19: 319-24. DOI: 10.1097/00006454-200004000-00011

8. Lee B.E., Cheung P.Y., Robinson J.L., Evanochko C., Robertson C.M. Comparative study of mortality and morbidity in premature infants (birth weight, 1250 g) with candidemia or candidalImeningitis. Clin Infect Dis. 1998; 27: 559-65. DOI: 10.1086/514712

9. Greenberg R.G., Benjamin D.K. Jr, Gantz M.G., Cotten C.M., Stoll B.J., Walsh M.C., et al. Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr. 2012; 161: 264-9. DOI: 10.1016/j.jpeds.2012.01.053

10. Manzoni P., Mostert M., Castagnola E. Update on the management of Candida infections in preterm neonates. Arch Dis Child Fetal Neonatal Ed. 2015; 100: F454-9. DOI: 10.1136/archdischild-2012-303350

11. Benjamin D.K. Jr., Stoll B.J., Gantz M.G., Walsh M.C., Sanchez PJ., Das A., et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010; 126: e865-73. DOI: 10.1542/peds.20 093412

12. Adams-Chapman I., Bann C.M., Das A., Goldberg R.N., Stoll B.J., Walsh M.C., et al. Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. J Pediatr. 2013; 163: 961-7. DOI: 10.1016/j.jpeds.2013.04.034

13. Roilides E., Farmaki E., Evdoridou J., Dotis J., Hatziioannidis E., Tsivitanidou M., et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis. 2004; 23: 745-50. DOI: 10.1007/s10096-004-1210-9

14. Sandven P., Bevanger L., Digranes A., Haukland H.H., Mannsa-ker T., Gaustad P Norwegian yeast study group. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol. 2006; 44: 1977-81. DOI: 10.1128/JCM.00029-06

15. Rodriguez D., Almirante B., Park B.J., Cuenca-Estrella M., Planes A.M., Sanchez F., et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J. 2006; 25: 224-9. DOI: 10.1097/01. inf.0000202127.43695.06

16. Blyth C.C., Chen S.C., Slavin M.A., Serena C., Nguyen Q., Marriott D., et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009; 123: 1360-8. DOI: 10.1542/peds.2008-2055

17. Neu N., Malik M., Lunding A., Whittier S., Alba L., Kubin C., et al. Epidemiology of candidemia at a Children’s hospital, 2002 to 2006. Pediatr Infect Dis J. 2009; 28: 806-9. DOI: 10.1097/INF.0b013e3181a0d78d

18. Chitnis A.S., Magill S.S., Edwards J.R., Chiller T.M., Fridkin S.K., Lessa F.C. Trends in Candida central line-associated bloodstream infections among NICUs, 1999-2009. Pediatrics. 2012; 130: e46-52. DOI: 10.1542/peds. 2011-3620

19. Bliss J.M., Wong A.Y., Bhak G., Laforce-Nesbitt S.S., Taylor S., Tan .S, et al. Candida virulence properties and adverse clinical outcomes in neonatal candidiasis. J Pediatr. 2012; 161: 441-7. DOI: 10.1016/ j.jpeds.2012.02.051

20. Taylor B.N., Fichtenbaum C., Saavedra M., Slavinsky I.J., Swobo-da R., Wozniak K., et al. In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus. J Infect Dis. 2000; 182: 955-9. DOI: 10.1086/315768

21. Shin J.H., Kee S.J., Shin M.G., Kim S.H., Shin D.H., Lee S.K., et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol. 2002; 40: 1244-8. DOI: 10.1128/ JCM.40.4.1244-12 48.2002

22. Pinto E., Ribeiro I.C., Ferreira N.J., Fortes C.E., Fonseca P.A., Figueiral M.H. Correlation between enzyme production, germ tube formation and susceptibility to fluconazole in Candida species isolated from patients with denture-related stomatitis and control individuals. J Oral Pathol Med. 2008; 37: 587-92. DOI: 10.1111/j.1600-0714.2008.00687.x

23. Cassone A., De Bernardis F., Pontieri E., Carruba G., Girmenia C., Martino P., et al. Biotype diversity of Candida parapsilosis and its relationship to the clinical source and experimental pathogenicity. J Infect Dis. 1995; 171: 967-75. DOI: 10.1093/infdis/171.4.967

24. De Bernardis F., Mondello F., Scaravelli G., Pachi A., Girolamo A., Agatensi L., et al. High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women. J Clin Microbiol. 1999; 37: 1376-80.

25. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003; 2: 114-22. DOI: 10.1038/nrd1008

26. Greengerg R.G., Benjamin D.K. Jr. Neonatal candidiasis: diagnosis, prevention and treatment. J Infect. 2014; 69: S19-22. DOI: 10.1016/ j.jinf.2014.07.012

27. Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Os-troskyZeichner L., et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016; 62: 1-50. DOI: 10.1093/cid/civ1194

28. Kaufman D.A. Neonatal candidiasis: clinical manifestations, management, and prevention strategies. J Ped. 2010; 156 (Suppl 2): A1-S86. DOI: 10.1016/j.jpeds.2009.11.074

29. Kliegman R.M., Stanton B.F., Schor N.F., Geme III, J.W., St. Beh-rman R.E. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: Elsevier Saunders Edition; 2011: 1054.

30. Auriti C., Falcone M., Ronchetti M.P., Goffredo B.M., Cairoli S., Cri-safulli R., et al. High-dose micafungin for preterm neonates and infants with invasive and central nervous system candidiasis. Antimicrob Agents Che-mother. 2016; 60: 7333-9. DOI: 10.1128/AAC.01172-16

31. Natarajan G., Lulic-Botica M., Rongkavilit C., Pappas A., Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol. 2005; 25: 770-7. DOI: 10.1038/sj.jp. 7211380

32. Hope W.W., Castagnola E., Groll A.H., Roilides E., Akova M., Aren-drup M.C., et al. ESCMID** guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012; 18 (Suppl 7): 38-52. DOI: 10.1111/1469-0691.12040

33. Cohen-Wolkowiez M., Benjamin D.K. Jr., Piper L., Cheifetz I.M., Moran C., Liu P, et al. Safety and pharmacokinetics of multiple-dose anidu-lafungin in infants and neonates. Clin Pharmacol Ther. 2011; 89: 702-7. DOI: 10.1038/clpt.2011.26

34. Clerihew L., McGuire W. Antifungal therapy for newborn infants with invasive fungal infection. Cochrane Neonatal Group. 2012; 6:CD003953. DOI: 10.1002/14651858.CD003953.pub3

35. Wilke M.H. Invasive fungal infections in infants-focus on anidula-fungin. Clin Med Insights Pediatr. 2013; 7: 7-11. DOI: 10.4137/CMPed. S8028

36. Zhao L., Jiang J., Zhu Z., Liao Z., Yao X., Yang Y., et al. Lysine enhances the effect of amphotericin B against Candida albicans in vitro. Acta Biochim Biophys Sin. 2015; 48: 182-93. DOI: 10.1093/abbs/gmv125

37. Autmizguine J., Guptill J.T., Cohen-Wolkowiez M., Benjamin D.K. Jr,. Capparelli E.V. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs. 2014; 74: 891-909. DOI: 10.1007/ s40265-014-0227-3

38. Frattarelli D.A., Reed M.D., Giacoia G.P., Aranda J.V. Antifungals in systemic neonatal candidiasis. Drugs. 2004; 64: 949-68. DOI: 10.2165/00003495-200464090-00003

39. Rybak J.M., Marx K.R., Nishimoto A.T., Rogers P.D. Isavuconazole; pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015; 35: 1037-51. DOI: 10.1002/phar.1652

40. Moen M.D., Lyseng-Williamson K.A., Scott L.J. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009; 69: 361-92. DOI: 10.2165/00003495-200969030-00010

41. Bradley J.S., Barnett E.D., Cantey J.B. Nelson’s Pediatric Antimicrobial Therapy. 24° edition©-2018. Itasca, IL: American Academy of Pediatrics.

42. Jeon J.W., Koo S.H., Lee J.H., Hwang J.H., Kim S.S., Lee E.K., et al. A comparison of ambisome to amphotericin B for treatment of sistemic candidiasis in very low birth weight infants. Yonsei Med J. 2007; 48: 619-26. DOI: 10.3349/ymj.2007.48.4.619

43. Pana Z.D., Kougia V., Roilides E. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update. Expert Opin Pharmacother. 2015; 16: 693-710. DOI: 10.1517/14656566.2015. 1013936

44. Reicher J., Flidel-Rimon O., Amitay M., Even-Tov S., Shinwell E., Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis. 2003; 22: 603-7. DOI: 10.1007/s10096-003-0993-4

45. Ohata Y., Tomita Y., Suzuki K., Maniwa T., Yano Y., Sunakawa K. Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: population approach in Japanese pediatrics. Drug Metab Pharm. 2015; 30: 400-9. DOI: 10.1016/j.dmpk.2015. 08.003

46. Wade K.C., Wu D., Kaufman D.A., Ward R.M., Benjamin D.K. Jr., Sullivan J.E., et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008; 52: 4043-9. DOI: 10.1128/ AAC.00569-08

47. Bradley J.S., Nelson JD. Nelson’s Pediatric Antimicrobial Therapy 2012-2013. 19th Edn. Itasca, IL: American Academy of Pediatrics.

48. Saxen H., Hoppu K., Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther. 1993; 54: 269-77. DOI: 10.1038/clpt.1993.147

49. Momper J.D., Capparelli E.V., Wade K.C., Kantak A., Dhanireddy R., Cummings J.J., et al. Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams. Antimicrob Agents Chemother. 2016; 60: 5539-45. DOI: 10.1128/AAC.00963-16

50. Kullberg B.J., Thompson G., Pappas P.G., Vazquez J., Viscoli C., Ostrosky Zeichner L., et al. Isavuconazole versus caspofungin in the treatment of candidaemia and other invasive Candida infections: the ACTIVE trial abstract No: #1239. In: 26th European Congress of Clinical Microbiology and Infectious Diseases ECCMID 26th (2016) Conference Abstracts. Amsterdam; 2016.

51. Mendiratta D.K., Rawat V., Thamke D., Chaturvedi P., Chhabra S., Narang P. Candida colonization in preterm babies admitted to neonatal intensive care unit in the rural setting. Indian J Med Microbiol. 2006; 24: 263-7. DOI: 10.4103/0255-0857.29384

52. Kicklighter S.D., Springer S.C., Cox T., Hulsey T.C., Turner R.B. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics. 2001; 107: 293-8. DOI: 10.1542/ peds.107.2.293

53. Kaufman D., Boyle R., Hazen K.C., Patrie J.T., Robinson M., Dono-witz L.G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001; 345: 1660-6. DOI: 10.1056/ NEJMoa 010494

54. Kaufman D., Boyle R., Hazen K.C., Patrie J.T., Robinson M., Grossman L.B. Twice weekly fluconazole prophylaxis for prevention of invasive candida infection in high-risk infants of <1000 grams birth weight. J Pediatr. 2005; 147: 172-9. DOI: 10.1016/j.jpeds.2005.03.036

55. Manzoni P., Stolfi I., Pugni L., Decembrino L., Magnani C., Ve-trano G., et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007; 356: 2483-95. DOI: 10.1056/ NEJMoa065733

56. Bertini G., Perugi S., Dani C., Filippi L., Pratesi S., Rubaltelli F.F. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr. 2005; 147: 162-5. DOI: 10.1016/ j.jpeds.2005. 02.020

57. Wiederhold N.P., Lewis R.E. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs. 2003; 12: 1313-33. DOI: 10.1517/13543784.12.8.1313

58. Denning D.W. Echinocandin antifungal drugs. Lancet. 2003; 362: 1142-51. DOI: 10.1016/S0140-6736(03)14472-8

59. Odds F.C., Brown A.J., Gow N.A. Antifungal agents: mechanisms of action. Trends Microbiol. 2003; 11: 272-9. DOI: 10.1016/S0966-842X(03)00117-3

60. Zaas A.K., Alexander B.D. Echinocandins: role in antifungal therapy, 2005. Expert Opin Pharmacother. 2005; 6: 1657-68. DOI: 10.1517/ 14656566.6.10.1657

61. Aguilar-Zapata D., Petraitiene R., Petraitis V. Echinocandins: the expanding antifungal armamentarium. Clin Infect Dis. 2015; 61: S604-11. DOI: 10.1093/cid/civ814

62. De Pauw B. Is there a need for new antifungal agents? Clin Microbiol Infect. 2000; 6: 23-8. DOI: 10.1046/j.1469-0691.2000.00006.x

63. Swaminathan S., Kamat S., Pinto N.A. Echinocandins: their role in the management of Candida biofilms. Indian J Med Microbiol. 2018; 36: 87-92. DOI: 10.4103/ijmm.IJMM_17_400

64. Odio C.M., Araya R., Pinto L.E., Castro C.E., Vasquez S., Alfaro B., et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J. 2004; 23: 1093-7. DOI: 10.1097/01.inf.0000145408. 51526.0a

65. Saez-Llorens X., Macias M., Maiya P., Pineros J., Jafri H.S., Chat-terjee A., et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother. 2009; 53: 869-75. doi: 10.1128/AAC.00868-08

66. Ascher S., Smith P.B., Benjamin D.K. Jr. Safety of micafungin in infants: insight to optimal dosing. Expert Opin Drug Saf. 2011; 10: 281-6. DOI: 10.1517/14740338.2011.545345

67. Yanni S.B., Smith P.B., Benjamin D.K. Jr., Augustijns P.F., Thak-ker D.R., Annaert P.P. Higher clearance of micafungin in neonates compared to adults: role of age dependent micafungin serum binding. Biopharm Drug Dispos. 2011; 32: 222-32. DOI: 10.1002/bdd.752

68. Wasmann R.E., Muilwijk E.W., Burger D.M., Verweij P.E., Knib-be C.A., Brdggemann R.J. Clinical pharmacokinetics and pharmacodynamics of micafungin. Clin Pharmacokinet. 2018; 57: 267-86. DOI: 10.1007/s40262-017-0578-5

69. Manzoni P., Wu C., Tweddle L., Roilides E. Micafungin in premature and nonpremature infants. A systematic review of 9 clinical trials. Pediatr Infect Dis J. 2014; 33: e291-8. DOI: 10.1097/INF.000000000000 0434

70. Astellas Pharma Inc. FDA Approves Pediatric Indication for Astellas MYCAMINE (Micafungin Sodium) for Injection. Tokyo: Astellas Pharma Inc; 2013.

71. EMA. Mycamine: EPAR-Product Information; 2018. EMEA/H/C/ 000734- R/0034.

72. Piersigilli F., Auriti C., Bersani I., Goffredo B., Bianco G., Savarese I., et al. Antifungal lock therapy with combined 70% ethanol and micafungin in a critically ill infant. Pediatr Infect Dis J. 2014; 33: 419-20. DOI: 10.1097/ INF.0000000000000116

73. Auriti C., Piersigilli F., Ronchetti M.P., Campi F., Amante P.G., Falcone M., et al. Shunt lock therapy with micafungin to treat shunt-associated Candida albicans meningitis in an infant. J Antimicrob Chemother. 2016; 71: 2060-1. DOI: 10.1093/jac/dkw072

74. Mathis R.K., Andres J.M., Walker W.A. Liver disease in infants. Part II: hepatic disease states. J Pediatr. 1977; 90: 864-80. DOI: 10.1016/ S0022-3476(77)80553-2

75. Sharma D., Choudhary M., Shastri S., Sharma P.K. Neonatal liver abscesses due to Candida infection in a preterm infant, secondary to mal-positioned umbilical lines - a rare entity. Pathog Global Health. 2015; 109: 84-7. DOI: 10.1179/2047773215Y.0000000008

76. Cascio A., Pantaleo D, Corona G., Barberi G., Delfino D., Romeo O., et al. Neonatal liver abscesses associated with candidemia: three cas-esand review of literature. J Matern Fetal Neonatal Med. 2014; 27: 743-9. DOI: 10.3109/14767058.2013.837878

77. Kawaguchi C., Arai I., Yasuhara H., Sano R., Nishikubo T., Taka-hashi Y. Efficacy of micafungin in treating four premature infants with candidiasis. Pediatr Int. 2009; 51: 220-4. DOI: 10.1111/j.1442-200X.2008. 02726.x

78. Petraitis V., Petraitiene R., Groll A.H., Roussillon K., Hemmings M., Lyman C.A, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2002; 46: 1857-69. DOI: 10.1128/AAC.46.6.1857-1869.2002

79. van Rossem K., Lowe J.A.. A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation. Clin Pharmacol. 2013; 5: 23-31. DOI: 10.2147/CPAA.S39600

80. Karlowicz M.G., Hashimoto L.N., Kelly R.E. Jr., Buescher E.S. Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics. 2000; 106: E63. DOI: 10.1542/peds. 106.5.e63

81. Wolf J., Shenep J.L., Clifford V., Curtis N., Flynn P.M. Ethanol lock therapy in pediatric hematology and oncology. Pediatr Blood Cancer. 2013; 60: 18-25. DOI: 10.1002/pbc.24249

82. Walraven C.J., Lee S.A. Antifungal lock therapy. Antimicrob Agents Chemother. 2013; 57: 1-8. DOI: 10.1128/AAC.01351-12

83. Carratala J. The antibiotic-lock technique for therapy of ’highly needed’ infected catheters. Clin Microbiol Infect. 2002; 8: 282-9. DOI: 10.1046/j.1469-0691.2002.00388.x

84. El Helou G., Viola G.M., Hachem R., Han X.Y., Raad I.I. Rapidly growing mycobacterial bloodstream infections. Lancet Infect Dis. 2013; 13: 166-74. DOI: 10.1016/S1473-3099(12)70316-X

85. Taylor J.E., Tan K., Lai N.M., McDonald S.J. Antibiotic lock for the prevention of catheter-related infection in neonates. Cochrane Database Syst Rev. 2015; 4: CD010336. DOI: 10.1002/14651858.CD010336.pub2

86. Filippi L., Poggi C., Gozzini E., Meleleo R., Mirabile L., Fiorini P. Neonatal liver abscesses due to Candida infection effectively treated with caspofungin. Acta Paediatr. 2009; 98: 906-9. DOI: 10.1111/j.1651-2227.2009.01225.x

87. Tan N.W., Sriram B., Tan-Kendrick A.P, Rajadurai V.S. Neonatal hepatic abscess in preterm infants:a rare entity? Ann Acad Med Singapore. 2005; 34: 558-64.

88. Siegel M.J. Liver and biliary tract. In: Siegel M.J, ed. Pediatric Sonography. 2nd ed. New York, NY: Raven Press; 1995: 193-5.

89. Gerzof S.G., Johnson W.C., Robbins A.H., Nabseth D.C. Intrahepatic pyogenic abscesses: treatment by percutaneous drainage. Am J Surg. 1985; 149: 487-94. DOI: 10.1016/S0002-9610(85)80045-3

90. Auriti C., Ronchetti M.P., Bersani I., Gennari F., Piersigilli F. Intrahepatic administration of liposomal amphotericin B (Ambisome) for the management of a liver abscess from Candida albicans in a preterm infant. Antimicrob Agents Chemother. 2018; 62: e01239-18. DOI: 10.1128/ AAC.01239-18

91. Katragkou A., Chatzimoschou A., Simitsopoulou M., Dalakiouri-dou M., DizaMataftsi E, Tsantali E.-D., et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother. 2008; 52: 357-60. DOI: 10.1128/ AAC.00856-07

92. Fiori B., Posteraro B., Torelli R., Tumbarello M., Perlin D.S., Fadda G., et al. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob Agents Chemother. 2011; 55: 3031-5. DOI: 10.1128/ AAC.01569-10

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Degtyarev Dmitriy Nikolaevich
Doctor of Medical Sciences, Professor, Deputy Director for Scientific Research of the V.I. Kulakov Obstetrics, Gynecology and Perinatology National Medical Research Center of Ministry of Healthсаre of the Russian Federation, Head of the Chair of Neonatology at the Clinical Institute of Children's Health named after N.F. Filatov, I.M. Sechenov First Moscow State Medical University, Chairman of the Ethics Committee of the Russian Society of Neonatologists, Moscow, Russian Federation

ORCID iD 0000-0001-8975-2425

Journals of «GEOTAR-Media»